Average recommended screening intervals by type of diabetes in individuals who either developed R2 (preproliferative retinopathy), R3A (active proliferative retinopathy) or M1 (diabetic maculopathy) within 2 years or not
| Average screening interval (months) | Reduction in screening frequency (%) | |||
|---|---|---|---|---|
| Regime | Without R2, R3 or M1 | With R2, R3, or M1 | ||
| Type I | 2 years ceiling | 23.7 | 22.7 | 48.9 |
| Type II | 2 years ceiling | 20.3 | 13.5 | 40.0 |
The results are shown for intervals with a 6 months floor and a 24 months ceiling. The last column shows the resulting reduction in the annual number of screenings of the population when applying the corresponding screening regime. With a 2 years ceiling, the mean recommended screening interval is 13.5 months for the patients with type II diabetes who develop R2, R3A or M1 within 2 years and 20.3 months for those who do not. The overall reduction in screening frequency in patients with type II diabetes is 40%.